BRPI0412761A - inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc - Google Patents

inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc

Info

Publication number
BRPI0412761A
BRPI0412761A BRPI0412761-7A BRPI0412761A BRPI0412761A BR PI0412761 A BRPI0412761 A BR PI0412761A BR PI0412761 A BRPI0412761 A BR PI0412761A BR PI0412761 A BRPI0412761 A BR PI0412761A
Authority
BR
Brazil
Prior art keywords
ns4a
protease
compounds
serine protease
vhc
Prior art date
Application number
BRPI0412761-7A
Other languages
English (en)
Inventor
Shawn D Britt
Kevin M Cottrell
Robert B Perni
Janos Pitlik
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34079432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412761(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BRPI0412761A publication Critical patent/BRPI0412761A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"INIBIDORES DE SERINO PROTEASES, PARTICULARMENTE A PROTEASE NS3-NS4A DO VHC". A presente invenção refere-se aos compostos da fórmula I ou a fórmula Ia ou sais farmaceuticamente aceitáveis dos mesmos, que inibem a atividade de serino protease, particularmente a atividade da protease do vírus NS3-NS4A da hepatite C. Como tal, eles agem interferindo com o ciclo de vida do vírus da hepatite C e são úteis como agentes antivirais. A invenção adicionamente refere-se às composições farmaceuticamente aceitáveis que compreendem os ditos compostos para o uso ex vivo ou para a administração a um paciente que sofre da infecção por VHC e dos processos para preparar os compostos. A invenção refere-se também aos métodos para tratar uma infecção de VHC em um paciente administrando uma composição farmacêutica que compreende um composto desta invenção.
BRPI0412761-7A 2003-07-18 2004-07-16 inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc BRPI0412761A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48853503P 2003-07-18 2003-07-18
PCT/US2004/023054 WO2005007681A2 (en) 2003-07-18 2004-07-16 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Publications (1)

Publication Number Publication Date
BRPI0412761A true BRPI0412761A (pt) 2006-09-26

Family

ID=34079432

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412761-7A BRPI0412761A (pt) 2003-07-18 2004-07-16 inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc

Country Status (19)

Country Link
US (2) US7109172B2 (pt)
EP (3) EP2368900A3 (pt)
JP (2) JP4745230B2 (pt)
KR (2) KR20120013450A (pt)
CN (3) CN1852920B (pt)
AR (1) AR045916A1 (pt)
AU (2) AU2004257288A1 (pt)
BR (1) BRPI0412761A (pt)
CA (1) CA2532664A1 (pt)
HK (1) HK1098164A1 (pt)
IL (2) IL173180A0 (pt)
NO (1) NO20060706L (pt)
NZ (1) NZ544789A (pt)
PE (1) PE20050251A1 (pt)
RU (1) RU2412198C2 (pt)
TW (1) TW200523270A (pt)
UY (1) UY28423A1 (pt)
WO (1) WO2005007681A2 (pt)
ZA (1) ZA200601420B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
CA2405043A1 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2005535574A (ja) * 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UY28423A1 (es) * 2003-07-18 2005-02-28 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TW200526686A (en) 2003-09-18 2005-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SI1677827T1 (sl) * 2003-10-27 2009-06-30 Vertex Pharma Zdravilni sestavek proti virusu hepatitisa c (hcv)
US7683033B2 (en) * 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
BRPI0610737A2 (pt) * 2005-06-02 2010-07-20 Schering Corp formulações farmacêuticas e métodos de tratamento usando as mesmas
CN101277950B (zh) * 2005-08-02 2013-03-27 弗特克斯药品有限公司 丝氨酸蛋白酶抑制剂
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
KR20080072906A (ko) 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
JP5436864B2 (ja) 2006-02-27 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む共結晶体およびそれを含む医薬組成物
MX2008011868A (es) 2006-03-16 2008-12-15 Vertex Pharma Inhibidores deuterados de la proteasa de la hepatitis c.
BRPI0710878A2 (pt) * 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
AU2007272839B2 (en) 2006-07-13 2012-05-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
TW200827364A (en) * 2006-11-02 2008-07-01 Taigen Biotechnology Co Ltd HCV protease inhibitors
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
SI2114924T1 (sl) 2007-02-27 2012-06-29 Vertex Pharma Ko-kristali in farmacevtski sestavki, ki jih vsebujejo
CA2696053A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN102245599B (zh) 2008-12-10 2014-05-14 艾其林医药公司 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
PT2477980T (pt) 2009-09-15 2016-08-31 Taigen Biotechnology Co Ltd Inibidores de protease de hcv
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
MX2012007420A (es) 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
CA2794181A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
WO2011159826A2 (en) 2010-06-15 2011-12-22 Vertex Pharmaceuticals Incorporated Hcv ns5b protease mutants
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2585448A1 (en) 2010-06-28 2013-05-01 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
AR081691A1 (es) 2010-06-28 2012-10-10 Vertex Pharma Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
AR087346A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Formulaciones de compuestos de tiofeno
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CN105408317A (zh) 2013-03-14 2016-03-16 艾其林医药公司 用于生产Sovaprevir的方法
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
WO2020117849A1 (en) 2018-12-04 2020-06-11 Bristol-Myers Squibb Company Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DE69934104T2 (de) 1998-03-31 2007-06-28 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von hepatitis c virus ns3 protease
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CA2405043A1 (en) 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
CN102372764A (zh) * 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN100402549C (zh) 2001-07-11 2008-07-16 沃泰克斯药物股份有限公司 桥连二环的丝氨酸蛋白酶抑制剂
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
JP2005535574A (ja) * 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
CA2495843A1 (en) 2002-09-04 2004-03-18 Mark Straubhaar Optoelectronic device for the treatment of muscle or joint pain
JP2006526011A (ja) * 2003-04-11 2006-11-16 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UY28423A1 (es) 2003-07-18 2005-02-28 Vertex Pharma Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
TW200526686A (en) 2003-09-18 2005-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7683033B2 (en) * 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases

Also Published As

Publication number Publication date
WO2005007681A2 (en) 2005-01-27
EP2341065A3 (en) 2012-06-20
EP2341065A2 (en) 2011-07-06
EP2368900A2 (en) 2011-09-28
AR045916A1 (es) 2005-11-16
PE20050251A1 (es) 2005-04-13
CN1852920B (zh) 2010-12-15
AU2010257200B2 (en) 2011-10-20
ZA200601420B (en) 2007-06-27
JP4745230B2 (ja) 2011-08-10
CN101724022A (zh) 2010-06-09
RU2006105002A (ru) 2006-08-27
CN1852920A (zh) 2006-10-25
EP2368900A3 (en) 2012-07-04
JP2008500265A (ja) 2008-01-10
CN102020700A (zh) 2011-04-20
AU2004257288A1 (en) 2005-01-27
US20050107304A1 (en) 2005-05-19
NZ544789A (en) 2010-01-29
IL173180A0 (en) 2006-06-11
KR20120013450A (ko) 2012-02-14
US7109172B2 (en) 2006-09-19
UY28423A1 (es) 2005-02-28
RU2412198C2 (ru) 2011-02-20
JP2011116784A (ja) 2011-06-16
TW200523270A (en) 2005-07-16
KR20060052836A (ko) 2006-05-19
US20060211629A1 (en) 2006-09-21
US8691758B2 (en) 2014-04-08
NO20060706L (no) 2006-02-14
HK1098164A1 (en) 2007-07-13
WO2005007681A3 (en) 2005-06-02
AU2004257288A2 (en) 2008-06-26
EP1646642A2 (en) 2006-04-19
IL218698A0 (en) 2012-05-31
CA2532664A1 (en) 2005-01-27
AU2010257200A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
WO2005077969A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005037860A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ATE349463T1 (de) Verbrückte bizyklische serinproteaseinhibitoren
ATE447573T1 (de) Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
BR112013006693A2 (pt) inibidores da serino protease hcv derivada de prolina macrocílcica
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MY155851A (en) Quinoxaline-containing compounds as hepatitis c virus inhibitors
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
MX2009009176A (es) Inhibidores de serina-proteasas.
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
WO2004113365A3 (en) Hepatitis c serine protease tri-peptide inhibitors
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.
TH104730A (th) การยับยั้งโปรตีเอส ns3-ns4a ของ hcv

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.